From rapid-acting analogs to insulin pumps, learn how modern insulin therapy helps people with type 1 and type 2 diabetes achieve glucose targets, reduce complications, and improve quality of life.
- What Is Insulin Therapy and Who Needs It?
- Types of Insulin: Rapid, Short, Intermediate, Long & Combination
- When Is Insulin Therapy Started in Type 2 Diabetes?
- How to Start Insulin: Initiation Protocols and Dose Adjustment
- Monitoring Blood Glucose on Insulin Therapy
- Side Effects and Risks: Hypoglycemia, Weight Gain, Lipodystrophy
- Common Myths About Insulin Therapy Debunked
- Frequently Asked Questions
What Is Insulin Therapy and Who Needs It?
Insulin therapy is the cornerstone of treatment for all individuals with type 1 diabetes and for many with type 2 diabetes who no longer achieve adequate glycemic control with oral agents and lifestyle measures. Insulin is a peptide hormone produced by the beta cells of the pancreas; it facilitates glucose uptake into cells, suppresses hepatic glucose production, and regulates lipid and protein metabolism.
In type 1 diabetes, absolute insulin deficiency necessitates lifelong exogenous insulin. In type 2 diabetes, progressive beta-cell dysfunction often leads to relative insulin deficiency, making exogenous insulin necessary over time. According to the American Diabetes Association (ADA) Standards of Care 2026, insulin therapy should be considered when HbA1c remains above 7.0% (53 mmol/mol) despite two or more non-insulin agents, or when patients present with severe hyperglycemia (glucose ≥300 mg/dL or HbA1c ≥10%).
The ADA defines intensive insulin therapy as a regimen designed to mimic physiologic insulin secretion — typically multiple daily injections (MDI) or continuous subcutaneous insulin infusion (CSII) — with self-monitoring of blood glucose and dose adjustments to achieve near-normal glucose levels.
Types of Insulin: Rapid, Short, Intermediate, Long & Combination
Insulin formulations differ by onset, peak, and duration of action. The choice of insulin type depends on the patient’s lifestyle, mealtime schedule, and glycemic patterns. Below is a practical comparison of commonly prescribed insulins in 2026.
| Type | Generic Name (Brand) | Onset | Peak | Duration | Typical Use |
|---|---|---|---|---|---|
| Rapid-acting | Insulin lispro (Humalog), aspart (NovoLog), glulisine (Apidra), faster-acting aspart (Fiasp) | 5–15 min | 1–2 h | 3–5 h | Mealtime coverage, postprandial glucose control |
| Short-acting | Regular insulin (Humulin R, Novolin R) | 30–60 min | 2–3 h | 5–8 h | Mealtime or intravenous use in hospital settings |
| Intermediate-acting | NPH insulin (Humulin N, Novolin N) | 1–2 h | 4–8 h | 12–18 h | Basal coverage (often twice daily) |
| Long-acting (analogs) | Insulin glargine (Lantus, Basaglar, Toujeo), detemir (Levemir), degludec (Tresiba) | 1–2 h | Minimal/Flat | ≥24 h (degludec up to 42 h) | Once-daily basal insulin |
| Ultra-long acting | Insulin icodec (Awiqli) – once-weekly basal | Slow | None | 7 days | Weekly injection for type 2 diabetes (2025 FDA-approved) |
| Premixed | 70/30 NPH/regular, 75/25 lispro protamine/lispro, 50/50, etc. | 15–60 min | 1–8 h | 10–16 h | Convenience for patients on fixed meal schedules |
Mixing different insulin types (e.g., NPH with rapid-acting) requires careful technique. Never mix insulin degludec or glargine with other insulins in the same syringe unless specifically approved by a manufacturer. Always consult a diabetes educator.
When Is Insulin Therapy Started in Type 2 Diabetes?
The decision to initiate insulin in type 2 diabetes is based on a combination of clinical factors. The ADA recommends considering insulin when:
- HbA1c ≥ 7.0% (53 mmol/mol) on two or more non-insulin agents (metformin + SGLT2 inhibitor/GLP-1 RA) with lifestyle optimization.
- Symptomatic hyperglycemia (polyuria, polydipsia, weight loss) with random glucose ≥300 mg/dL (16.7 mmol/L).
- Ketosis-prone diabetes or evidence of severe insulin deficiency (e.g., low C-peptide).
- Hospitalization or surgery where tight glycemic control is needed.
- Pregnancy — insulin is the preferred agent for gestational diabetes and pre-existing diabetes in pregnancy.
A common clinical scenario is a patient with a 10-year history of type 2 diabetes who has gradually required higher doses of sulfonylureas and GLP-1 receptor agonists but still has fasting glucose levels above 180 mg/dL. The ADA’s type 2 diabetes algorithm (2026 update) lists basal insulin as the first injectable after oral combination failure.
“Basal insulin remains the most straightforward and evidence-based first injectable agent for type 2 diabetes, providing predictable fasting glucose control with low risk of hypoglycemia when titrated appropriately.”
— ADA Professional Practice Committee, 2026
How to Start Insulin: Initiation Protocols and Dose Adjustment
Starting insulin can feel overwhelming, but a structured approach — often called “basal-bolus” or “basal-only” — simplifies the process. Below are the step-by-step recommendations from the ADA and the American Association of Clinical Endocrinology (AACE).
Monitoring Blood Glucose on Insulin Therapy
Effective insulin therapy requires regular glucose monitoring. The frequency and method depend on the insulin regimen.
- Basal-only therapy: Check fasting glucose at least once daily. Consider checking before dinner occasionally to detect basal insufficiency.
- Basal-bolus (MDI): Check glucose before each meal and at bedtime (4–6 times/day). Postprandial checks (1–2 hours after starting a meal) help fine-tune mealtime doses.
- Insulin pump (CSII): CGM is the standard of care. Interstitial glucose readings guide bolus delivery, temporary basal rates, and automated insulin suspension for hypoglycemia prevention.
- Goal ranges (ADA 2026): Preprandial 80–130 mg/dL (4.4–7.2 mmol/L); postprandial peak <180 mg/dL (10.0 mmol/L); HbA1c <7.0% (<53 mmol/mol) for most nonpregnant adults. Individualize for older adults or those with comorbidities (e.g., HbA1c <8.0%).
A 2025 meta-analysis of 22 RCTs showed that patients using CGM with insulin therapy achieved 0.7% greater HbA1c reduction and 50% fewer severe hypoglycemic events compared with self-monitored blood glucose alone. If available, prescribe a real-time CGM (e.g., Dexcom G7, FreeStyle Libre 3) for patients on MDI or pump therapy.
Side Effects and Risks: Hypoglycemia, Weight Gain, Lipodystrophy
While insulin is life-saving, it carries potential adverse effects that require proactive management.
If a patient is unconscious or cannot swallow, do not give oral glucose. Administer 1 mg glucagon intramuscularly or intranasal glucagon (Baqsimi). Call 911 immediately. All patients on insulin should have a glucagon prescription and a caregiver trained in its use.
Common Myths About Insulin Therapy Debunked
Many patients resist starting insulin due to misconceptions. Here are the most prevalent myths, with evidence-based clarifications.
False. Type 2 diabetes is a progressive disease; beta-cell function declines over time regardless of how well a patient manages lifestyle. Adding insulin is a natural, evidence-based step to preserve health, not a failure. The DCCT/EDIC trial (NEJM 1993) proved that intensive insulin therapy reduces long-term complications by 50–60%.
False. Insulin does not cause diabetic complications. On the contrary, achieving near-normal glucose levels with insulin is the most effective way to prevent retinopathy and nephropathy. The ACCORD and ADVANCE trials confirmed that intensive glucose control reduces albuminuria and retinopathy progression.
Partially true, but manageable. Weight gain of 2–6 kg is common initially. However, a structured program combining insulin with metformin, GLP-1 receptor agonists, and medical nutrition therapy can minimize gain. Many newer insulins (e.g., insulin icodec) show similar weight profiles to standard analogs.
False. With modern ultra-fine needles (4mm, 32G), most patients report minimal pain — far less than a fingerstick. Many type 2 patients use only one daily basal injection. Pumps and patch devices (e.g., Omnipod) further reduce injection burden. A diabetes educator can teach pain-free injection techniques.
Frequently Asked Questions
Can insulin therapy cause hypoglycemia?
Yes, hypoglycemia is the most common acute complication of insulin therapy. It occurs when glucose drops below 70 mg/dL. Risk is higher during dose adjustments, after missed meals, or with increased physical activity. Structured titration algorithms and CGM greatly reduce severe hypoglycemia. Always carry fast-acting glucose and a glucagon kit.
What is the difference between insulin glargine, detemir, and degludec?
All three are long-acting basal insulins, but they differ in duration and variability. Glargine (Lantus) lasts ~24 hours; detemir (Levemir) lasts 16–18 hours (often needs twice daily dosing); degludec (Tresiba) lasts >42 hours with a flat profile, offering lower risk of nocturnal hypoglycemia. Degludec can be flexibly dosed 8–40 hours apart. Icodec (Awiqli) is once-weekly.
Do I need to stop metformin when starting insulin?
No. Metformin is recommended as first-line therapy alongside insulin in type 2 diabetes unless contraindicated (e.g., eGFR <15 mL/min). Combination therapy improves glycemic control with lower insulin doses and less weight gain. Continue metformin unless your doctor advises otherwise.
How do I travel with insulin?
Insulin should be stored at 36–46°F (2–8°C) until opened. Unopened vials can be refrigerated until expiry. Once opened, most insulins are stable at room temperature (59–86°F) for up to 28 days. For air travel, carry insulin in your carry-on, use a cooling bag (e.g., Frio pouch), and request a letter from your doctor explaining your medical needs. Never expose insulin to extreme heat or freezing.
Can I use insulin if I have kidney or liver disease?
Yes, but dose adjustments are often needed. Insulin clearance is reduced in advanced chronic kidney disease (CKD stage 4–5), so insulin requirements may decrease. Patients on dialysis require careful monitoring. In liver cirrhosis, gluconeogenesis is impaired, raising hypoglycemia risk. Always involve a nephrologist or hepatologist in dose decisions. CGM is particularly helpful in these populations.
